Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis | Zendy

Yingxin Xu | Zendy; Kyle Fahrbach | Zendy; Emily Dorman | Zendy; Simona Baculea | Zendy; Sarah Côté | Zendy; Suzy Van Sanden | Zendy; Joris Diels | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis

Author(s) -

Yingxin Xu,

Kyle Fahrbach,

Emily Dorman,

Simona Baculea,

Sarah Côté,

Suzy Van Sanden,

Joris Diels

Publication year - 2017

Publication title -

journal of comparative effectiveness research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.567

H-Index - 23

eISSN - 2042-6313

pISSN - 2042-6305

DOI - 10.2217/cer-2017-0086

Subject(s) - medicine , ibrutinib , chronic lymphocytic leukemia , fludarabine , meta analysis , oncology , population , leukemia , chemotherapy , environmental health , cyclophosphamide

Aim: A systematic literature review and network meta-analysis were conducted to determine the relative efficacy and safety of interventions for treatment-naive chronic lymphocytic leukemia patients, as comparative evidence is scarce. Materials & methods: Relative treatment effects of progression-free survival, overall survival and safety outcomes were estimated via network meta-analysis based on data identified via systematic literature review. Results: Ibrutinib was superior in all pairwise comparisons for progression-free survival (probability to be better [P] range: overall population: 69–100%; fludarabine-ineligible population: 69–100%) and overall survival (P range: overall: 89–100%; fludarabine-ineligible: 91–100%) and had the highest probability of being best for all outcomes. Conclusion: Ibrutinib provides superior benefit in survival and safety compared with other front-line treatments of chronic lymphocytic leukemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research